Expediting in Vitro Characterization of mRNA-Based Gene Therapies via High-Content Fluorescent Imaging


Authors: T.N. Vigila, D. Zhang-Hulsey, J.L. Santos and G.P. Hussmann

Journal: Analytical Biochemistry

DOI: https://doi.org/10.1016/j.ab.2021.114259

Publication - Abstract

August 15, 2021

mRNA Nucleic Acid Lipid Nanoparticles
A study conducted by Vigil et al. 2021 from Astrazeneca Biopharmaceuticals R&D showcases the applicability of high-content fluorescent imaging as a technique for the rapid characterization of mRNA-LNPs generated from a NanoAssemblr® mixing device in order to determine the optimal conditions for transfection that minimize cellular cytotoxicity and maximize mRNA internalization. Through high-content fluorescent imaging, mRNA-LNP characteristics such as transfection parameters, transfection-induced cytotoxicity, mRNA delivery, and mRNA translation were investigated in HEPG2 two dimensional monolayer and three dimensional spheroid cell cultures. This research demonstrates the value in utilizing high fluorescent imaging especially for future studies toward the development of novel gene therapies and drug candidates for various disease areas.

limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

May 29, 2020
Scientific Reports

Lipid Nanoparticle Formulation Increases Efficiency of DNA-Vectored Vaccines/Immunoprophylaxis in Animals Including Transchromosomic Bovines

E.M. Mucker, P.P. Karmali, J. Vega, S.A. Kwilas, H. Wu, M. Joselyn, J. Ballantyne, D. Sampey, R. Mukthavaram, E. Sullivan, P. Chivukula and J.W. Hooper

DNA Nucleic Acid Lipid Nanoparticles Vaccines
The use of nucleic acid as a drug substance for vaccines and other gene-based medicines continues to evolve. Here, we have used a technology originally developed for mRNA in vivo delivery to enhance the immunogenicity of DNA vaccines. We demonstrate that neutralizing antibodies p...
Read More


Publication - Abstract

Nov 30, 2019
Journal of Controlled Release

Lipid Nanoparticles of Type-A CpG D35 Suppress Tumor Growth by Changing Tumor Immune-microenvironment and Activate CD8 T Cells in Mice

L. Munakata, Y. Tanimoto, A. Osa, J. Meng, Y. Haseda, Y. Naito, H. Machiyama, A. Kumanogoh, D. Omata, K. Maruyama, Y. Yoshioka, Y. Okada, S. Koyama, R. Suzuki, and T. Aoshi

Oncology Nucleic Acid Lipid Nanoparticles mRNA
Type-A CpG oligodeoxynucleotides (ODNs), which have a natural phosphodiester backbone, is one of the highest IFN-α inducer from plasmacytoid dendritic cells (pDC) via Toll-like receptor 9 (TLR9)-dependent signaling. However, the in vivo application of Type-A CpG has been li...
Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up